AxoGen, Inc. provided preliminary earnings guidance for the fourth quarter and full year ended December 31, 2022. For the quarter, the company revenue is expected to be approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 2021.

For the year, the company expects revenue to be approximately $138.5 million, a 12% increase compared to 2021 excluding the impact of Avive revenue in 2021.